Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

13.42
+0.57004.44%
Post-market: 13.450.0300+0.22%18:42 EDT
Volume:729.55K
Turnover:9.59M
Market Cap:812.26M
PE:-3.60
High:13.51
Open:12.82
Low:12.63
Close:12.85
52wk High:16.74
52wk Low:5.68
Shares:60.53M
Float Shares:43.02M
Volume Ratio:0.73
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7236
EPS(LYR):-3.7236
ROE:-44.02%
ROA:-28.22%
PB:1.99
PE(LYR):-3.60

Loading ...

Taiho, Cullinan Therapeutics initiate rolling submission of NDA for zipalertinib

TIPRANKS
·
Nov 21, 2025

Optimistic Buy Rating for Cullinan Management Driven by Promising Drug Pipeline and Upcoming Catalysts

TIPRANKS
·
Nov 21, 2025

Cullinan Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 21, 2025

Cullinan Therapeutics price target raised to $26 from $24 at H.C. Wainwright

TIPRANKS
·
Nov 21, 2025

Cullinan Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $26 From $24

THOMSON REUTERS
·
Nov 20, 2025

Cullinan, Taiho Submit New Drug Application for Zipalertinib in Lung Cancer

MT Newswires Live
·
Nov 20, 2025

Taiho Oncology Inc: Anticipate Completion of Nda Submission in Q1 2026 With Associated Request for Priority Review

THOMSON REUTERS
·
Nov 20, 2025

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations

THOMSON REUTERS
·
Nov 20, 2025

Cullinan Therapeutics and Partners Begin FDA Rolling Submission for Zipalertinib in EGFR-Mutant NSCLC

Reuters
·
Nov 20, 2025

Cullinan Therapeutics Q3 Operating Expenses USD 55.595 Million

Reuters
·
Nov 20, 2025

Cullinan Management’s Promising Pipeline and Strategic Collaborations Drive Buy Rating

TIPRANKS
·
Nov 12, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at ASH Annual Meeting

Reuters
·
Nov 10, 2025

Cullinan Therapeutics Reports Increased Q3 Losses

TIPRANKS
·
Nov 07, 2025

Cullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating

TIPRANKS
·
Nov 07, 2025

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM)

TIPRANKS
·
Nov 07, 2025

Cullinan Management’s Promising Pipeline and Strategic Focus Earns Buy Rating

TIPRANKS
·
Nov 07, 2025

Cullinan Management Reports Strong Q3 2025 Financial Results

TIPRANKS
·
Nov 06, 2025

Cullinan Therapeutics Q3 EPS $(0.77) Beats $(0.95) Estimate

Benzinga
·
Nov 06, 2025

Cullinan Therapeutics reports Q3 EPS (77c), consensus (89c)

TIPRANKS
·
Nov 06, 2025

Cullinan Therapeutics posts Q3 net loss of $50.6 million on $475.5 million cash position

Reuters
·
Nov 06, 2025